Basiliximab induction improves the outcome of renal transplants in children and adolescents

Thirty-two children and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four patients received basiliximab, in addition to tacrolimus and steroids (basiliximab group). The remaining eight patients received only tacr...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric nephrology (Berlin, West) West), 2001-09, Vol.16 (9), p.693-696
Main Authors: SWIATECKA-URBAN, Agnieszka, GARCIA, Clotilde, FEUERSTEIN, Dianne, SUZUKI, Samuel, DEVARAJAN, Prasad, SCHECHNER, Richard, GREENSTEIN, Stuart, TELLIS, Vivian, KASKEL, Frederick
Format: Article
Language:English
Subjects:
Adolescent
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Basiliximab
Biological and medical sciences
Child
Child, Preschool
Diabetes Mellitus - etiology
Disease prevention
Drug dosages
Female
Humans
Immunomodulators
Immunosuppressive Agents - therapeutic use
Kidney Transplantation - adverse effects
Kidney Transplantation - mortality
Kidney transplants
Lymphoproliferative Disorders - etiology
Male
Medical schools
Medical sciences
Medicine
Patients
Pharmacology. Drug treatments
Recombinant Fusion Proteins
Steroids
Survival Rate
Teenagers
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty-two children and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four patients received basiliximab, in addition to tacrolimus and steroids (basiliximab group). The remaining eight patients received only tacrolimus and steroids (non-basiliximab group). The 1-year patient survival rate was 100% in both groups. The 1-year graft survival rate was 87.5% for the basiliximab group and 75% for the non-basiliximab group (P=0.45). The rates of acute rejection in the basiliximab and non-basiliximab groups were 26% and 43%, respectively (P=0.36). However, in recipients with
ISSN:0931-041X
1432-198X
DOI:10.1007/s004670100642